We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
NVIDIA
NVDA
$5.01T
| $19.3M | 0.26% |
4,444,680
-538,640
| -11% | -$2.27M |
|
77
Estee Lauder
EL
$29B
| $19.3M | 0.26% |
96,781
-14,701
| -13% | -$2.81M |
|
78
Newmont
NEM
$98.2B
| $19.1M | 0.25% |
504,284
-119,151
| -19% | -$4.63M |
|
79
McDonald's
MCD
$188B
| $19.1M | 0.25% |
88,828
+6,521
| +8% | +$1.4M |
|
80
Danaher
DHR
$135B
| $19M | 0.25% |
148,547
-61,372
| -29% | -$7.68M |
|
81
Heron Therapeutics
HRTX
$86.3M
| $18.6M | 0.25% |
1,006,600
+338,000
| +51% | +$6.22M |
|
82
SLB Ltd
SLB
$77.8B
| $18.5M | 0.25% |
541,562
-79,537
| -13% | -$2.91M |
|
83
Neurocrine Biosciences
NBIX
$17.7B
| $18.4M | 0.24% |
204,669
-63,000
| -24% | -$5.89M |
|
|
SGEN
84
DELISTED
Seagen Inc. Common Stock
SGEN
| $18.4M | 0.24% |
215,780
-74,000
| -26% | -$5.43M |
|
85
Dollar General
DG
$25.9B
| $18.3M | 0.24% |
115,071
+44,559
| +63% | +$6.45M |
|
86
Dentsply Sirona
XRAY
$2.59B
| $18.1M | 0.24% |
340,073
-13,572
| -4% | -$729K |
|
87
IBM
IBM
$202B
| $18.1M | 0.24% |
130,260
-72,390
| -36% | -$9.76M |
|
|
KYNB
88
Kyntra Bio
KYNB
$28.5M
| $18M | 0.24% |
19,516
+17,476
| +857% | +$19.2M |
|
|
ARQL
89
DELISTED
Arqule Inc
ARQL
| $18M | 0.24% |
2,505,237
-250,000
| -9% | -$2.35M |
|
|
ADSW
90
DELISTED
Advanced Disposal Services Inc
ADSW
| $17.7M | 0.24% |
544,456
+367,939
| +208% | +$11.9M |
|
91
Labcorp
LH
$24.3B
| $17.6M | 0.23% |
121,938
-3,120
| -2% | -$455K |
|
92
Ionis Pharmaceuticals
IONS
$9.35B
| $17.6M | 0.23% |
293,200
| – | – |
|
|
BHVN
93
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $17.5M | 0.23% |
419,799
-38,000
| -8% | -$1.61M |
|
94
Applied Materials
AMAT
$426B
| $17.4M | 0.23% |
348,561
-65,720
| -16% | -$3.17M |
|
95
Southwest Airlines
LUV
$22.1B
| $17.3M | 0.23% |
319,570
-22,279
| -7% | -$1.17M |
|
96
Comcast
CMCSA
$79.1B
| $17.2M | 0.23% |
382,126
-71,021
| -16% | -$3.15M |
|
|
ATVI
97
DELISTED
Activision Blizzard
ATVI
| $17.2M | 0.23% |
325,026
-148,535
| -31% | -$7.41M |
|
98
Qualcomm
QCOM
$176B
| $17.1M | 0.23% |
223,840
+48,206
| +27% | +$3.63M |
|
99
Intuit
INTU
$81.1B
| $17.1M | 0.23% |
64,157
-2,321
| -3% | -$638K |
|
100
S&P Global
SPGI
$126B
| $17M | 0.23% |
69,519
+269
| +0.4% | +$67.2K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.